{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 13:50:37", "close_timestamp": 1637934637150, "created": "26/11/2021 13:50:37", "department": "Management with Marketing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "a54b19f1-f70f-49e3-8fb2-72a3b083e801", "open_date_time": "2021-10-26 13:46:20", "open_timestamp": 1637934380174, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "From my analysis, similarly to the first take, researchers have gone above and beyond to try a find a cure that would, if approved, be given the all-clear by the FDA and save lives.", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 256976, "what": "Finding a cure for COVID-19", "when_happened": "few_month_ago", "where_location": " Monash University", "who": "Dr Kylie Wagstaff, people, world. ", "why": "It's a cure that will save lives if deemed successful."}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 14:2:48", "close_timestamp": 1637935368921, "created": "26/11/2021 14:02:50", "department": "Management with Marketing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "67c52502-8f4f-4da9-be9b-6a9e842327e1", "open_date_time": "2021-10-26 13:54:22", "open_timestamp": 1637934862876, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Despite testing over 30,000 participants, as there are so many variants, they are finding it very challenging to make that all in one vaccine that would eliminate all variants.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 506045, "what": "Successful Vaccine Trials", "when_happened": "current_month", "where_location": " South Africa and India", "who": " Participants", "why": "It's important as they are making progress"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 13:54:19", "close_timestamp": 1637934859188, "created": "26/11/2021 13:54:19", "department": "Management with Marketing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "ce58506c-2a7f-4ca1-92ad-8c93574af6e3", "open_date_time": "2021-10-26 13:50:50", "open_timestamp": 1637934650425, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Professors and researchers are working endlessly to find a vaccine. They are going frustrated that things are taking so long.", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 208763, "what": "Ivermectin triple therapy", "when_happened": "few_month_ago", "where_location": "Monash University in April", "who": "Kylie Wagstaff's team", "why": "Finding a suitable vaccine"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 13:45:41", "close_timestamp": 1637934341449, "created": "26/11/2021 13:45:43", "department": "Management with Marketing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "a74ea083-589f-45f2-aa34-155066a0873c", "open_date_time": "2021-10-26 13:33:20", "open_timestamp": 1637933600954, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "From the information I have gathered, Japan has taken appropriate measures in finding a resolution for COVID-19.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 740495, "what": "COVID-19", "when_happened": "today", "where_location": "Japan", "who": "people, patients, government, outpatients, Dr Osamu Okuda, president", "why": "Ultimately, the story is important because it portrays how they came by the decision to approve the Cocktail Ronapreve. This will avoid backlash and press are its a thorough process they've undergone. "}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 14:21:1", "close_timestamp": 1637936461722, "created": "26/11/2021 14:21:04", "department": "Management with Marketing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "fdbc7616-68c2-43e7-8c76-8e4335b6f72f", "open_date_time": "2021-10-26 14:9:56", "open_timestamp": 1637935796753, "summary": "The constant battle the government face with anti-vaxxers has become very frustrating. This is due to them radicalising the ones who ultimately want to get it, but, can you blame them? Theirs so much we are uneducated on in regards to this virus that has caused havoc to our lives for well over 18 months. Japan-based Sosei Group (TYO: 4565) recently published they have something in clinical trials and it's showing progress. \r\n\r\nOne must be aware, as this is a completely new virus, that even professors themselves are educating themselves on as they create these vaccines, no one knows the long-lasting effects it could potentially have on each individual.", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 664969}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_23", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-26 14:9:32", "close_timestamp": 1637935772318, "created": "26/11/2021 14:09:33", "department": "Management with Marketing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "b79d320b-75e8-4642-8353-3b6afe8898e1", "open_date_time": "2021-10-26 14:2:56", "open_timestamp": 1637935376183, "summary": "Despite many governments being pushy, so much that they are offering incentives for people to get vaccinated - it's extremely tough for people to make a decision whether to get the vaccine EMA finds possible link of AstraZeneca's COVID-19 vaccine with rare blood clots.\r\n\r\nThis is contradictory as people would be taking the vaccine for their health and wellbeing, but ultimately also putting themselves in danger of having a possible blood clot. Only a minority have suffered this, nevertheless physiologically, you can't blame people for being hesitant about this so-called medicine. \r\n\r\nFurther to this, the UK suggests that coronavirus vaccines from Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and AstraZeneca (LSE: AZN), are effective against the so-called Indian variant, but this is only one variant, what about the rest?", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 396135}}}